Effects of desglycinamide-arginine-vasopressin (DG-AVP) on memory processes in diabetes insipidus patients and non-diabetic subjects.
The effects of desglycinamide9-arginine8-vasopressin (DG-AVP) on memory processes have been studied in patients with central diabetes insipidus (DI) and in non-diabetic control patients. Acute im injection of DG-AVP improved some aspects of short-term memory. Subchronic intranasal administration of DG-AVP facilitated short-term memory more consistently and in addition improved long-term memory. DG-AVP increased the attention, but only in the non-diabetic subjects. The effects of DG-AVP on memory processes persisted after discontinuation of treatment. DG-AVP did not affect the parameters for water and electrolyte metabolism, blood pressure and pulse rate neither in DI nor in the control patients. Thus, the memory effects of DG-AVP are probably mediated by a direct action on the central nervous system.
D000293:Adolescent; D000328:Adult; D001127:Arginine Vasopressin / Q000031:analogs & derivatives* / Q000494:pharmacology; D001288:Attention / Q000187:drug effects; D003919:Diabetes Insipidus / Q000523:psychology*; D005260:Female; D006801:Humans; D008297:Male; D008568:Memory / Q000187:drug effects*; D008570:Memory, Short-Term / Q000187:drug effects; D009483:Neuropsychological Tests; D011581:Psychological Tests
D001127:Arginine Vasopressin; C015119:argipressin, des-GlyNH2(9)-